A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ImmunoGen, Inc.
With
Gynecologic Oncology Group
Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
Participants must have folate receptor alpha positive tumor expression as defined in the protocol
Participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy.
Participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment
Participants must have at least one lesion that meets the definition of measurable disease by RECIST 1.1
You may not be if
Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
Participants with primary platinum-refractory disease
Serious concurrent illness or clinically relevant active infection as defined in the protocol
Prior treatment with mirvetuximab soravtansine
Women who are pregnant or breast feeding
Clareo Health | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
